Reference no: EM134008070

Patent Law and Pharmaceutical IndustryPatent Law and Pharmaceutical Industry

Question 1

A pharmaceutical company, PharmaCo, develops a new drug, XYZ-123, which it sells to a research institution, LIU, under a confidentiality agreement six month before filing a patent application. This sale includes the delivery of XYZ-123 and detailed documentation about its formulation and use, although it remains undisclosed to the public. Considering the on-sale bar provisions under U.S. patent law, which of the following best describes the impact of this secret sale on PharmaCo's ability to secure a patent for XYZ-123?

The secret sale may trigger the on-sale bar, potentially rendering XYZ-123 unpatentable, because the sale occurred before the patent application was filed, regardless of the confidentiality of the sale.

The secret sale has no impact on the patentability of XYZ-123 because the sale was confidential and not public knowledge

The on-sale bar does not apply because the sale involved a transfer of proprietary information under a confidentiality agreement, which is considered an exception under U.S. patent law.

The on-sale bar is only applicable if the sale was made to another commercial entity, so the sale to LIU, a research institution, does not affect the patentability of CureAll

Question 2

Given the Supreme Court's decision in the Myriad case, which of the following would be an acceptable focus for a pharmaceutical company developing a new diagnostic method?

Patenting naturally occurring gene sequences that have been merely isolated from the human body

Developing a novel method for analyzing gene sequences without claiming the sequences themselves

Identifying and claiming new naturally occurring gene sequences

Claiming the biological functions of naturally occurring gene sequences

Question 3

A pharmaceutical company, PharmaCo, has developed a groundbreaking antibody that targets a specific protein associated with a rare form of cancer. PharmaCo applies for a patent for their antibody, but the patent office has concerns regarding the enablement of the claimed invention, similar to the issues faced in Amgen Inc. v. Sanofi. The patent office argues that PharmaCo's patent application does not sufficiently describe how a person skilled in the art could make and use the full scope of the claimed invention without undue experimentation.

Which of the following best represents the issue PharmaCo faces in obtaining their patent, as highlighted by the enablement requirement in Amgen Inc. v. Sanofi?

PharmaCo's patent application lacks novelty because the antibody targets a known protein.

PharmaCo's patent application is too broad, covering all antibodies targeting the specific protein without sufficiently teaching how to make and use them.

PharmaCo's patent application is not inventive because it applies known techniques to discover the antibody.

PharmaCo failed to pay the required fees for patent application processing, leading to a rejection based on administrative grounds.

Question 4

In the district court litigation of Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., Idenix claimed that Gilead's hepatitis C drugs, Sovaldi and Harvoni, infringed on one of its patents. The patent in question covered a method of treating hepatitis C by administering certain nucleoside analogs. Gilead countered that the patent was invalid for reasons including lack of enablement and obviousness. The jury initially found in favor of Idenix, awarding a significant sum in damages, but the decision was subject to further legal scrutiny regarding the patent's validity and the scope of the claims.

Which of the following best describes the primary legal issue addressed in the district court litigation of Idenix Pharmaceuticals LLC v. Gilead Sciences Inc.?

Whether Gilead Sciences Inc. had the right to market Sovaldi and Harvoni without obtaining a license from Idenix Pharmaceuticals LLC.

Whether Idenix Pharmaceuticals LLC's patent on a method of treating hepatitis C was valid and enforceable against Gilead Sciences Inc.

Whether the damages awarded to Idenix Pharmaceuticals LLC were calculated accurately based on Gilead Sciences Inc.'s profits from Sovaldi and Harvoni.

Whether Gilead Sciences Inc.'s Sovaldi and Harvoni were safe and effective treatments for hepatitis C, as approved by the FDA.